Evidence map›Paper›PMID 28733430›Full record

Trial reportJournal of the American Heart Association2017

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.

Patrick R Lawler, Akintunde O Akinkuolie, Audrey Y Chu, Svati H Shah, William E Kraus, Damian Craig, Latha Padmanabhan, Robert J Glynn, Paul M Ridker, Daniel I Chasman and 1 more

Registry-linked trialOpen access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00239681 (A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin), which is not on this map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00239681 phase3terminatednot on this map

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

TypeinterventionalSponsorAstraZenecaRan2003 to 2008Enrolled17,802ConditionsElevated High-sensitivity C-Reactive Protein (hsCRP)ArmsRosuvastatin, Placebo
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Patrick R LawlerCenter for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Akintunde O AkinkuolieCenter for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Audrey Y ChuPreventive Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Svati H ShahDivision of Cardiology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
William E KrausDivision of Cardiology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Damian CraigDivision of Cardiology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Latha PadmanabhanPreventive Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Robert J GlynnCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Paul M RidkerCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Daniel I ChasmanPreventive Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Samia MoraCenter for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA smora@partners.org.
Brigham and Women's Hospital · USDuke University · USHarvard University · USHeart and Stroke Foundation · CA

Funding

Training Program in the Epidemiology of CVDT32HL007575 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BURING, JULIE E., RIDKER, PAUL M. · 1985 to 2019
$5.0M
Total plasma and IgG glycomes, statin therapy and ASCVD eventsR01HL117861 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2013 to 2022
$3.8M
NHLBI NIH HHS R01 HL117861NHLBI NIH HHS T32 HL007575
6 · The paper itself

Abstract

backgroundLevels of LDL (low-density lipoprotein) cholesterol in the population are declining, and increasing attention is being focused on residual lipid-related pathways of atherosclerotic cardiovascular disease risk beyond LDL cholesterol. Among individuals with low (<130 mg/dL) LDL cholesterol, we undertook detailed profiling of circulating atherogenic lipoproteins in relation to incident cardiovascular disease in 2 populations. METHODS AND

resultsWe performed proton nuclear magnetic resonance spectroscopy to quantify concentrations of LDL and VLDL (very low-density lipoprotein) particle subclasses in 11 984 JUPITER trial participants (NCT00239681). Adjusted Cox models examined cardiovascular disease risk associated with lipoprotein measures according to treatment allocation. Risk (adjusted hazard ratio [95%CI] per SD increment) among placebo-allocated participants was associated with total LDL particles (1.19 [1.02, 1.38]) and total VLDL particles (1.21 [1.04, 1.41]), as well as apolipoprotein B, non-high-density lipoprotein cholesterol, and triglycerides, but not LDL-c. Rosuvastatin reduced LDL measures but had variable effects on triglyceride and VLDL measures. On-statin levels of the smallest VLDL particle subclass were associated with a 68% per-SD (adjusted hazard ratio 1.68 [1.28, 2.22]) increase in residual risk-this risk was related to VLDL cholesterol and not triglyceride or larger VLDL particles. There was evidence that residual risk prediction during statin therapy could be significantly improved through the inclusion of key VLDL measures (Harrell C-index 0.780 versus 0.712;

conclusionsAtherogenic lipoprotein particle concentrations were associated with cardiovascular disease risk when LDL cholesterol was low. VLDL lipoproteins, particularly the smallest remnant subclass, may represent unused targets for risk prediction and potential therapeutic intervention for reducing residual risk. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

Indexed as

AgedAtherosclerosisBiomarkersCholesterol, LDLCholesterol, VLDLDown-RegulationDyslipidemiasFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedPrimary PreventionPrognosisProportional Hazards ModelsBiomarkersCholesterol, LDLCholesterol, VLDLHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin Calciumatherosclerosislipids and lipoproteinsmetabolomicsnuclear magnetic resonance spectroscopyprevention

Identifiers

PMID28733430
PMCPMC5586287
OpenAlexW2738941847

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.